BST2 (E4N3W) XP® Rabbit mAb (BSA and Azide Free) #38142
- WB
- IHC
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 28-40, 50-70 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
BST2 (E4N3W) XP® Rabbit mAb (BSA and Azide Free) recognizes endogenous levels of total BST2 protein. This clone shows a preference for the BST2 dimer by western blot.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with human BST2 recombinant protein.
Background
BST2 (CD317, Tetherin, HM1.24) is a type II transmembrane glycoprotein functioning as a major mediator of the innate immune defense against the dissemination of enveloped viruses by tethering virion on the cell surface (1). BST2 has an N-terminal cytoplasmic tail for endocytosis and cytoskeletal signaling, a transmembrane domain, an extracellular domain containing putative disulfide bonds and coiled-coil region for homodimer formation, and a C-terminal GPI domain for membrane anchoring (2,3). Both the transmembrane domain and the GPI domain can insert either into the cell membrane or the viral envelope membrane and hold them together to prevent viral release. Some viruses encode proteins, such as HIV-1 and Vpu, respectively, to act as antagonists to counteract BST2 (2,3). BST2 is overexpressed in gastrointestinal cancers, breast cancer, lung cancer, and multiple myeloma (4-7). BST2 monoclonal antibody targeting myeloma or lung cancer cells induces cellular cytotoxicity and cell death (ADCC, antibody-dependent cell-mediated cytotoxicity). Thus, BST2 serves as a potential target for tumor immunotherapy.
- Le Tortorec, A. et al. (2011) Viruses 3, 520-40.
- Douglas, J.L. et al. (2010) PLoS Pathog 6, e1000913.
- Kuhl, B.D. et al. (2011) J Neuroimmune Pharmacol 6, 188-201.
- Mukai, S. et al. (2016) Ann Surg Oncol, 594-602.
- Sayeed, A. et al. (2013) PLoS One 8, e67191.
- Wang, W. et al. (2009) Cancer Immunol Immunother 58, 967-76.
- Harada, T. and Ozaki, S. (2014) Biomed Res Int 2014, 965384.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.